CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025

CNS Pharmaceuticals, Inc.

Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.
Authorized common shares reduced from 300M to 25M; preferred from 5M to 416,667.
No fractional shares; cash in lieu for odd lots.
CUSIP changes to 18978H508; trading symbol CNSP unchanged.
Historical per-share data recast: FY2024 basic loss per share goes from ($38.87) pre-split to ($466.43) post-split.

item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.